54884-19-4

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-N,4-DIMETHYLBENZAMIDE is used as a pharmaceutical intermediate for its ability to facilitate the synthesis of various drugs and organic compounds. Its presence in the manufacturing process is essential for creating a wide range of medications and other organic substances.
Used in Research and Development:
3-AMINO-N,4-DIMETHYLBENZAMIDE is utilized as a subject of study for its potential therapeutic properties. Researchers in the pharmaceutical industry are interested in exploring its capabilities, which may contribute to the discovery of new treatments and advancements in medicine.

InChI:InChI=1/C9H12N2O/c1-6-3-4-7(5-8(6)10)9(12)11-2/h3-5H,10H2,1-2H3,(H,11,12)

Upstream product

• 2458-12-0 3-amino-p-toluic acid 
• 2592-95-2 benzotriazol-1-ol 
• 329940-36-5 N-methyl-3-nitro-4-methylbenzamide 
• 10397-30-5 4-methyl-3-nitrobenzoyl chloride 
• 96-98-0 4-methyl-3-nitrobenzoic acid 

Downstream Products

• 630107-80-1 Compound 4A 
• 482344-60-5 3-(6-chloro-pyrimidin-4-ylamino)-4,N-dimethyl-benzamide 
• 1005196-64-4 methyl 5-methyl-4-(2-methyl-5-(methylcarbamoyl)phenylamino)pyrrolo[1,2-f][1,2,4]triazine-6-carboxylate 
• 1023296-93-6 C₁₆H₁₈BrN₃O₃S 
• 1026765-63-8 C₂₀H₂₃N₅O₃ 
• 745078-00-6 5-amino-2-bromo-N,4-dimethylbenzamide 
• 482344-81-0 3-(5-bromo-2-chloro-pyrimidin-4-ylamino)-4,N-dimethyl-benzamide 

Relevant academic research and scientific papers

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4- oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clinical candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin- 3(4H)-yl]benzamide (AZD6703). Optimisation was guided by understanding of the binding modes from X-ray crystallographic studies which showed a switch from DFG 'out' to DFG 'in' as the inhibitor size was reduced to improve overall properties.

Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38α mitogen-activated protein kinase inhibitors

A novel structural class of p38 mitogen-activated protein (MAP) kinase inhibitors consisting of substituted 4-(phenylamino)-pyrrolo[2,1-f][1,2,4] triazines has been discovered. An initial subdeck screen revealed that the oxindole-pyrrolo[2,1-f][1,2,4]tria

PYRAZOLO-PYRIMIDINE ANILINE COMPOUNDS

Compounds having the formula (I), where all substituents are as defined herein, and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors.